A six-year-old girl died in March 2025 following an experimental gene-editing therapy administered at Xinhua Hospital in Shanghai, prompting a government investigation that led to the dismissal of the lead researcher.
Investigation Findings in Shanghai
Zilong Qiu, a neuroscientist at Shanghai Jiao Tong University School of Medicine, led the trial for a child diagnosed with Snijders Blok–Campeau syndrome.
According to a statement from the Shanghai municipal government, Qiu failed to inform clinical researchers at Xinhua Hospital about preclinical results showing liver damage in monkeys before the therapy proceeded. The investigation concluded that an early warning signal in the safety report was not given high attention.
I expect the action to send a big warning to research institutes and hospitals across the country, “I expect the action to send a big warning to research institutes and hospitals across the country,” said Jiayou Shi, a lawyer at the National Research Center for Civil and Commercial Law at Renmin University of China.
Qiu has been dismissed from his position as deputy director of the Songjiang Research Institution and barred from leading science projects for five years. Xinhua Hospital’s ethics committee was also penalized for approving the trial despite lacking necessary safety evidence, and the hospital failed to list death as a potential risk on the family’s consent form.

Pediatric Brain Cancer Research Stalls
In the United States, the termination of the Pediatric Brain Tumor Consortium has disrupted research for children with diffuse intrinsic pontine glioma (DIPG). In August 2025, the National Cancer Institute (NCI) ended the consortium’s $4 million annual grant, causing the immediate closure or pausing of eight ongoing clinical trials. The decision was part of a broader shift in federal research funding approaches under the Trump administration.
The consortium, which connected 16 pediatric hospitals, had been a central hub for testing novel treatments for DIPG, a fatal brain tumor that typically strikes children between 4 and 10 years old. The investigation is quite candid about what went wrong, said Lizzi Lee, a researcher at the Asia Society Policy Institute, regarding the broader need for clinical oversight in biotechnology.
Impact on Families and Clinical Enrollment
For families like the Schecters in Twinsburg, Ohio, the pause in trials has limited access to experimental care. Five-year-old Ryleigh Schecter currently receives a drug regimen that includes medication designed for breast cancer. Ryleigh describes the taste of her nightly medication as dirty water mixed together, which she follows with Skittles, noting, I don’t like the purple or the green.
Earlier coverage: US Childhood Cancer Survival Hits 90%, But Gains Are Uneven